首页 / 产品 / ELISA试剂盒 / 人ELISA试剂盒
产品描述：人GTP酶KRas(KRAS)酶联免疫试剂盒为双抗夹心法ELISA试剂盒，定量检测血清、血浆、组织匀浆样本中的KRAS含量。KRAS是重要的原癌基因，在细胞内信号传导通路中起关键作用。其突变与多种癌症的发生、发展密切相关，如胰腺癌、肺癌等。研究主要聚焦于抑制突变KRAS蛋白活性、阻断下游信号传导等机制，以开发针对性抗癌疗法。试剂盒检测范围为23.5 pg/mL-1500 pg/mL，适用于多种科研场景，包括肿瘤机制研究中KRAS信号通路的调控分析、癌症模型动物血清标志物水平监测，以及体外培养细胞或组织样本中KRAS表达量的定量评估，为探究KRAS相关分子机制、药物靶点筛选及病理模型构建提供可靠工具。本品仅用于科研，不用于临床诊断，产品具体参数及操作步骤详见产品说明书。
别名：c Ki ras2 ELISA Kit; c Kirsten ras protein ELISA Kit; c-K-ras ELISA Kit; c-Ki-ras ELISA Kit; Cellular c Ki ras2 proto oncogene ELISA Kit; Cellular transforming proto oncogene ELISA Kit; CFC2 ELISA Kit; cK Ras ELISA Kit; GTPase KRas ELISA Kit; K RAS p21 protein ELISA Kit; K RAS2A ELISA Kit; K RAS2B ELISA Kit; K RAS4A ELISA Kit; K RAS4B ELISA Kit; K-Ras 2 ELISA Kit; KI RAS ELISA Kit; Ki-Ras ELISA Kit; KIRSTEN MURINE SARCOMA VIRUS 2 ELISA Kit; Kirsten rat sarcoma 2 viral (v Ki ras2) oncogene homolog ELISA Kit; Kirsten rat sarcoma viral oncogene homolog ELISA Kit; KRAS ELISA Kit; KRAS proto oncogene, GTPase ELISA Kit; KRAS1 ELISA Kit; KRAS2 ELISA Kit; N-terminally processed ELISA Kit; NS ELISA Kit; NS3 ELISA Kit; Oncogene KRAS2 ELISA Kit; p21ras ELISA Kit; PR310 c K ras oncogene ELISA Kit; PR310 cK ras oncogene ELISA Kit; RALD ELISA Kit; RASK_HUMAN ELISA Kit; RASK2 ELISA Kit; Transforming protein p21 ELISA Kit; v Ki ras2 Kirsten rat sarcoma 2 viral oncogene homolog ELISA Kit; v Ki ras2 Kirsten rat sarcoma viral oncogene homolog ELISA Kit
缩写：KRAS
Uniprot No.：P01116
种属：Homo sapiens (Human)
样本类型：serum, plasma, tissue homogenates
检测范围：23.5 pg/mL-1500 pg/mL
灵敏度：5.8 pg/mL
反应时间：1-5h
样本体积：50-100ul
检测波长：450 nm
研究领域：Signal Transduction
测定原理：quantitative
测定方法：Sandwich
精密度：
| Intra-assay Precision (Precision within an assay): CV%<8% | ||||||
| Three samples of known concentration were tested twenty times on one plate to assess. | ||||||
| Inter-assay Precision (Precision between assays): CV%<10% | ||||||
| Three samples of known concentration were tested in twenty assays to assess. | ||||||
线性度：
| To assess the linearity of the assay, samples were spiked with high concentrations of human KRAS in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay. | ||||||
| Sample | Serum(n=4) | |||||
| 1:1 | Average % | 92 | ||||
| Range % | 86-102 | |||||
| 1:2 | Average % | 92 | ||||
| Range % | 86-108 | |||||
| 1:4 | Average % | 89 | ||||
| Range % | 82-98 | |||||
| 1:8 | Average % | 95 | ||||
| Range % | 88-100 | |||||
回收率：
| The recovery of human KRAS spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section. | ||||||
| Sample Type | Average % Recovery | Range | ||||
| Serum (n=5) | 93 | 90-97 | ||||
| EDTA plasma (n=4) | 88 | 83-92 | ||||
标准曲线：
| These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed. | ||||||
| pg/mlOD1OD2AverageCorrected15001.7561.8141.7851.6317501.0621.1231.0930.9393750.6380.6290.6340.480187.50.4270.4220.4250.271940.3030.3170.3100.156470.2540.2630.2590.10523.50.1960.2010.1990.04500.1510.1560.154 | ||||||
货期：3-5 working days
×
